ROCK2 as a novel target for diabetic cardiomyopathy
Por:
Soliman H., Nyamandi V., Hove-Madsen L., MacLeod K.M.
Publicada:
1 ene 2020
Resumen:
[No abstract available]
Filiaciones:
Soliman H.:
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British, Columbia, Canada and Faculty of Pharmacy, Minia University, Minia, Egypt
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British, Columbia, Canada
Nyamandi V.:
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British, Columbia, Canada
Hove-Madsen L.:
Biomedical Research Institute Barcelona IIBB-CSIC, IIB Sant Pau and CIBERCV, Hospital de Sant Pau, Barcelona, 08025, Spain
MacLeod K.M.:
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British, Columbia, Canada
|